Trade-Ideas LLC identified

Anika Therapeutics

(

ANIK

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Anika Therapeutics as such a stock due to the following factors:

  • ANIK has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $8.3 million.
  • ANIK has traded 1,513 shares today.
  • ANIK is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ANIK with the Ticky from Trade-Ideas. See the FREE profile for ANIK NOW at Trade-Ideas

More details on ANIK:

Anika Therapeutics, Inc., together with its subsidiaries, provides therapeutic pain management solutions for patients with degenerative orthopedic diseases and traumatic conditions in the United States, Canada, Europe, and internationally. ANIK has a PE ratio of 23. Currently there are 2 analysts that rate Anika Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Anika Therapeutics has been 163,200 shares per day over the past 30 days. Anika has a market cap of $719.0 million and is part of the health care sector and drugs industry. The stock has a beta of 1.63 and a short float of 11.4% with 9.86 days to cover. Shares are up 33.5% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Anika Therapeutics as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

  • The revenue growth greatly exceeded the industry average of 6.9%. Since the same quarter one year prior, revenues rose by 43.6%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • ANIK has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 12.02, which clearly demonstrates the ability to cover short-term cash needs.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, ANIKA THERAPEUTICS INC's return on equity exceeds that of both the industry average and the S&P 500.
  • The gross profit margin for ANIKA THERAPEUTICS INC is currently very high, coming in at 79.88%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 30.94% significantly outperformed against the industry average.
  • Net operating cash flow has significantly increased by 92.77% to $7.68 million when compared to the same quarter last year. In addition, ANIKA THERAPEUTICS INC has also vastly surpassed the industry average cash flow growth rate of -16.64%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.